E3 PreliminaryPreliminaryPEM ?Peer-reviewedMachine draft
Efficacy of neurotropin in chronic fatigue syndrome: a case report.
Toda, Katsuhiro, Kimura, Hiroaki · Hiroshima journal of medical sciences · 2006
Quick Summary
This case report describes one 28-year-old man with ME/CFS who was treated with a medication called Neurotropin (four tablets daily). His fatigue and widespread pain began improving within a week, and his sleep, focus, and memory improved within two weeks. He stopped taking the medication after 11 weeks and remained symptom-free for at least 5 months afterward.
Why It Matters
ME/CFS lacks FDA-approved treatments, and anecdotal reports of symptomatic improvement with novel therapies merit documentation. This case suggests Neurotropin may warrant further investigation in controlled clinical trials, though it remains largely unknown in Western medicine and requires replication before clinical recommendations can be made.
Observed Findings
- General fatigue and body-wide pain gradually resolved within one week of Neurotropin treatment
- Sleep quality, concentration, and memory improved by two weeks of treatment
- Patient discontinued medication after 11 weeks and remained symptom-free at 5-month follow-up
- Additional baseline symptoms included insomnia, memory decline, frequent urination, difficulty with emotional control, and lack of concentration
Inferred Conclusions
- Neurotropin may have therapeutic potential in treating CFS symptoms
- Symptomatic response may occur relatively rapidly (within one week) in some patients
- The mechanisms by which Neurotropin might benefit CFS remain unclear and require investigation
Remaining Questions
- What is the mechanism of action by which Neurotropin might improve CFS symptoms?
- Would Neurotropin show efficacy in a randomized controlled trial with a placebo arm?
- Does efficacy vary across the diverse clinical presentations and subtypes of ME/CFS?
- What is the optimal dosing regimen and treatment duration for potential future use?
What This Study Does Not Prove
This single case report cannot establish causation, efficacy, or safety of Neurotropin for ME/CFS. The natural history of CFS includes variable disease courses with spontaneous improvement; without a control group, placebo effect, or baseline disease trajectory data, it is impossible to determine whether the patient's improvement resulted from the medication or other factors. Results from one patient cannot be generalized to the broader ME/CFS population.
Tags
Symptom:Cognitive DysfunctionUnrefreshing SleepPainFatigue
Method Flag:PEM Not DefinedWeak Case DefinitionNo ControlsSmall SampleExploratory Only
Metadata
- PMID
- 16594551
- Review status
- Machine draft
- Evidence level
- Early hypothesis, preprint, editorial, or weak support
- Last updated
- 8 April 2026